title: miRNAs: mediators of ErbB family targeted therapy resistance.
abstract: The ErbB/HER tyrosine kinase receptors family plays a key regulatory role in different cellular processes by activating several signaling pathways. In different tumor types, mutations or overexpression of the ErbB family members are a common feature, which led to the development of targeted therapies against this receptors. Although with this kind of treatment we are heading to a more personalized medicine, the development of acquired resistance is still an issue, therefore, several studies focused on discovering the mechanisms behind it. More recently, miRNAs have been described as important mediators of acquired resistance, specifically, acquired resistance to ErbB family targeted therapies. Ultimately, miRNA-based therapeutics using exosomes as a drug delivery model can revolutionize today's approach of cancer treatment.
authors.affiliation: Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.|FMUP, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
authors.forename: Bárbara Filipa
authors.initials: BF
authors.lastname: Adem
authors.affiliation: Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.|FMUP, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
authors.forename: Nuno Ricardo Alves
authors.initials: NR
authors.lastname: Bastos
authors.affiliation: Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.|ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.|LPCC, Research Department Portuguese League Against Cancer (NRNorte), Estrada Interior da Circunvalação 6657, 4200 Porto, Portugal.
authors.forename: Francisca
authors.initials: F
authors.lastname: Dias
authors.affiliation: Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.|LPCC, Research Department Portuguese League Against Cancer (NRNorte), Estrada Interior da Circunvalação 6657, 4200 Porto, Portugal.
authors.forename: Ana Luísa
authors.initials: AL
authors.lastname: Teixeira
authors.affiliation: Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.|ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.|LPCC, Research Department Portuguese League Against Cancer (NRNorte), Estrada Interior da Circunvalação 6657, 4200 Porto, Portugal.|CEBIMED, Health Sciences of Fernando Pessoa University, Rua Carlos da Maia 296, 4200-150 Porto, Portugal.
authors.forename: Rui
authors.initials: R
authors.lastname: Medeiros
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D035683:MicroRNAs / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D018739:Oncogene Proteins v-erbB / Q000235:genetics* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; D018739:Oncogene Proteins v-erbB
keywords: ErbB family; acquired resistance; exosomes; miRNAs; targeted therapies